Minus und Minus iss immer BLUS
Seite 1 von 2 Neuester Beitrag: 25.04.21 01:26 | ||||
Eröffnet am: | 01.07.15 06:23 | von: buran | Anzahl Beiträge: | 26 |
Neuester Beitrag: | 25.04.21 01:26 | von: Annettbwnua | Leser gesamt: | 7.917 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
0 Postings ausgeblendet.
The lead program KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. The Phase III Confirmatory Study completed its enrollment in January 2015 and is expected to conclude in 2016.
KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare inflammatory condition that affects the lungs. A Phase II trial is expected to begin in the second half of 2015.
In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for treatment of sHUS are currently underway.
BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.
BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
- See more at: http://www.bellushealth.com/English/about-bellus/...ash.Ky3FxYUt.dpuf http://www.bellushealth.com/English/about-bellus/...file/default.aspx